<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189396</url>
  </required_header>
  <id_info>
    <org_study_id>API-A006-CL-C</org_study_id>
    <nct_id>NCT01189396</nct_id>
  </id_info>
  <brief_title>Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006</brief_title>
  <official_title>A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic
      profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active
      control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI)), and a Placebo DPI in
      escalating and cumulative-doses up to 1440 mcg, eight (8) times of the proposed clinical
      dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchodilatory efficacy after the escalating and cumulative-doses, up to 1,440 mcg.</measure>
    <time_frame>-15 min predose, 15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, 360 min post dose 4</time_frame>
    <description>Area Under the Curve (AUC)0-t of percent change in Forced Expiratory Volume in 1 second (FEV1), which is defined as the area under curve of post-dose FEV1 percentage changes from the Pre-dose Baseline FEV1 (FEV10) versus time. Doses are at 0, 30, 60 and 90 min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of change in FEV1</measure>
    <time_frame>-15, 15 min post 1, 2, and 3, and 15, 90, 120, 240, and 360min post dose 4</time_frame>
    <description>AUC of FEV1 volume post-dose changes (change in Volume) from the Pre-dose Baseline FEV1 (FEV10). Doses are at 0, 30, 60 and 90 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset</measure>
    <time_frame>0 - 120 min</time_frame>
    <description>Time to onset of bronchodilatory effect, determined by linear interpolation as the point where FEV1 % change first reaches ≥ 12% from FEV10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Response</measure>
    <time_frame>15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, and 360 min post dose 4</time_frame>
    <description>The peak bronchodilator response, defined as the maximum post-dose FEV1 % change. Doses are at time 0, 30, 60, and 90 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Time 0, 15, 45, 75, 105, 150, 195, 130, 190, 250, 435 minutes post dose 1</time_frame>
    <description>The adverse drug events (ADE) that are observed with Proventil-HFA may be expected with the use of A006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Analysis</measure>
    <time_frame>-15, 10, 25,40, 55, 70, 85, 95, 115, 145, 175, 210, 270, 330, 690 min post dose 1</time_frame>
    <description>serum glucose and potassium analysis and PK analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs and Electrocardiogram (ECG)</measure>
    <time_frame>-15, 5, 35, 65, 100, 155, 275, 455, 815 min post dose 1</time_frame>
    <description>vital signs, including pulse and blood pressure and 12-lead ECG</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Asthma</condition>
  <condition>Bronchospasm</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A006</intervention_name>
    <description>Albuterol DPI with 180 mcg Albuterol/inhalation</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo DPI</intervention_name>
    <description>Placebo DPI with 0 mcg Albuterol/inhalation</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proventil-HFA</intervention_name>
    <description>Albuterol MDI with 90 mcg Albuterol/inhalation</description>
    <arm_group_label>R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ≥ 50 kg for men and ≥ 45 kg for women, and BMI within the range of 18.5 -
             30.0 kg/m2 inclusive;

          -  Sitting blood pressure ≤ 135/90 mmHg;

          -  Demonstrating negative alcohol/drug screen tests;

          -  Demonstrating negative HIV, HBsAg and HCV-Ab screen tests;

          -  With mild-to-moderate persistent asthma for at least 6 months prior to Screening, and
             having used inhaled β-agonist(s) for asthma control;

          -  Demonstrating a Mean Screening Baseline FEV1 at 50.0 - 85.0 % of predicted normal;

          -  Demonstrating a ≥ 15.0% Airway Reversibility in FEV1 within 30(±5) min after inhaling
             2 actuations of Proventil-HFA;

          -  Demonstrating Peak Inspiratory Flow Rate within 80-150 L/min;

          -  Demonstrating proficiency in the use of DPI and MDI after training;

          -  Females of child-bearing potential must be non-pregnant, non-lactating, and practicing
             a clinically acceptable form of birth control;

          -  Having properly consented to participate in the trial.

        Exclusion Criteria:

          -  Smoking history of ≥ 10 pack-years, or having smoked within 6 months prior to
             Screening;

          -  Upper respiratory tract infections within 2 wk, or lower respiratory tract infection
             within 4 wk;

          -  Asthma exacerbations that required emergency care or hospitalized treatment, within 4
             wk prior;

          -  Any current or recent respiratory conditions that might significantly affect
             pharmacodynamic response to the study drugs, besides asthma;

          -  Concurrent clinically significant cardiovascular, hematological, renal, neurologic,
             hepatic, endocrine, psychiatric, malignancies, or other illnesses that could impact on
             the conduct, safety and evaluation of the study;

          -  Known intolerance or hypersensitivity to any of the ingredients of the A006 or
             Proventil-HFA;

          -  Use of prohibited drugs or failure to observe the drug washout restrictions;

          -  Having been on other clinical drug/device studies in the last 30 days;

          -  Having donated blood within the last 30 days prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safety Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Amphastar Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphastar Site 0025</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 0026</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 0032</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 0034</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahrens RC. The role of the MDI and DPI in pediatric patients: &quot;Children are not just miniature adults&quot;. Respir Care. 2005 Oct;50(10):1323-8; discussion 1328-30. Review.</citation>
    <PMID>16185368</PMID>
  </reference>
  <reference>
    <citation>Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur J Clin Pharmacol. 1987;32(6):631-4.</citation>
    <PMID>3653233</PMID>
  </reference>
  <reference>
    <citation>Hindle M, Newton DA, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. Chest. 1995 Mar;107(3):629-33.</citation>
    <PMID>7874928</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. Review.</citation>
    <PMID>15994402</PMID>
  </reference>
  <reference>
    <citation>Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68.</citation>
    <PMID>16264058</PMID>
  </reference>
  <reference>
    <citation>Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981 Jun;123(6):659-64.</citation>
    <PMID>7271065</PMID>
  </reference>
  <reference>
    <citation>Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir. 1982 May-Jun;18(3):419-25.</citation>
    <PMID>7074238</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <disposition_first_submitted>April 17, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 18, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 19, 2017</disposition_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>bronchospasm</keyword>
  <keyword>COPD</keyword>
  <keyword>reversibility</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Bronchial Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

